Altimmune (ALT) Prices 3.37M Share Common Offering at $23/Sh

After-Hours Stock Movers 07/13: (INMB) (VNDA) (FREQ) Higher; (OSMT) (MHK) (ALT) Lower (more...)

Today's After-Hours Stock Movers:

INmune Bio, Inc. (NASDAQ: INMB) 68.9% HIGHER; today reported clinical data demonstrating that its lead drug candidate, XPro1595, decreases neuroinflammation in patients with Alzheimers disease. Interim results from a Phase Ib clinical trial show that treatment with XPro1595 decreases white matter free water, a biomarker of neuroinflammation measured by MRI. XPro1595 is a next-generation inhibitor of tumor necrosis factor (TNF) that selectively neutralizes soluble TNF, an inflammatory cytokine implicated in Alzheimer's pathology, without affecting transmembrane TNF or the TNF receptors.

Osmotica Pharmaceuticals plc (Nasdaq:... More

Altimmune (ALT) Plans Offering of Common Stock and Pre-Funded Warrants

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering and, to certain investors in lieu thereof, pre-funded warrants to purchase shares of its common stock. Altimmune also expects to grant the underwriters a 30-day option to... More

Pre-Open Stock Movers 07/13: (BFYT) (ALT) (TSLA) Higher; (CLSN) Lower (more...)

Pre-Open Stock Movers

Celsion Corporation (NASDAQ: CLSN) 66.2% LOWER; announced that it has received a recommendation from the independent Data Monitoring Committee (DMC) to consider stopping the global Phase III OPTIMA Study of ThermoDox® in combination with radiofrequency ablation (RFA) for the treatment of hepatocellular carcinoma (HCC), or primary liver cancer.

Benefytt Technologies, Inc. (NASDAQ: BFYT) 37.5% HIGHER; announced that it has entered into a definitive agreement to be acquired by funds affiliated with Madison Dearborn Partners, LLC, a... More

Altimmune (ALT), University of Alabama at Birmingham Announce Positive Preclinical Results for Intranasal COVID-19 Vaccine Candidate, AdCOVID

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced positive results from the preclinical studies of its intranasal COVID-19 vaccine candidate, AdCOVID. The studies, which were conducted in collaboration with the University of Alabama at Birmingham (UAB), showed strong serum neutralizing activity and potent mucosal immunity in the respiratory tract. The induction of IgA antibody in the respiratory tract may be necessary to block both infection and transmission of the virus to prevent further spread of COVID-19. Based on these findings the Company plans to begin manufacturing of AdCOVID and advance the... More

Altimmune (ALT) call put ratio 2 calls to 1 put as shares rally 6%

Altimmune (NASDAQ: ALT) July weekly call option implied volatility is at 232, July is at 220; compared to its 52-week range of 89 to 352 as shares rally 6%. Call put ratio 2 calls to 1 put with focus on 22.50 calls.

Altimmune (ALT) options active on wide price movement

Altimmune (NASDAQ: ALT) July weekly call option implied volatility is at 290, July is at 230; compared to its 52-week range of 89 to 352. Call put ratio 2.4 calls to 1 put with focus on July 20 and 22.50 calls.